It’s hard to watch the news or scroll through social media without encountering stories about weight loss drugs like ...

Rybelsus is an oral form of semaglutide, the active ingredient in the company’s blockbuster Ozempic and Wegovy diabetes and weight-loss drugs, and was tested in the trial on diabetic patients ...

Novo Nordisk plans to file a label expansion for Rybelsus (oral semaglutide) as an adjunct treatment for the prevention of major adverse cardiovascular events (MACE) in patients with type 2 ...

Bernstein said Novo Nordisk’s (NVO) recently released SOUL study results for Rybelsus in the reduction of major cardiovascular events in diabetic patients were modest and not as robust as ...

Oral semaglutide, sold as Rybelsus, reduced the risk of a group of cardiovascular events by 14% compared with placebo in certain patients with Type 2 diabetes in a late-stage study, Novo said Monday.

The study showed that Rybelsus, the company's oral form of semaglutide, slashed the risk of major cardiovascular events by 14% in type 2 diabetes patients who also face cardiovascular or kidney ...

The EMA's main advisory committee has backed approval of Novo Nordisk's oral GLP-1 agonist Rybelsus, a key pipeline drug in its type 2 diabetes franchise. Rybelsus (semaglutide) is the first GLP-1 ...

Novo Nordisk's GLP-1 medication, Rybelsus, reduced major adverse cardiovascular events by 14% compared to a placebo in a phase 3 trial, the drugmaker said Oct. 21. Rybelsus, a daily pill approved ...